We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Upper GI
Digital Poster
Clinical
KRAS status as an independent prognostic factor for survival after SBRT Colorectal Cancer Liver Metastases
Manoela Cholakova, Bulgaria
E25-28
Patient-specific characteristics impact liver toxicity following liver SBRT
Vitali Moiseenko, USA
E25-577
Retrospective Analysis of Definitive Chemo-Radiotherapy for Oesophageal Carcinoma with Carboplatin and Paclitaxel
Hammad Hammad, United Kingdom
E25-584
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Esophageal Cancer Treated with Proton Beam Therapy
Kenji Makita, Japan
E25-585
Assessment of Suitability of PRV Margins Applied to Organs at Risk in Pancreatic Stereotactic Body Radiotherapy
Ahmed Eltinay, United Kingdom
E25-603
Adjuvant Radiotherapy in Patients with Gastric Signet-ring Cellular Carcinoma Undergone with Radical Surgery and Chemotherapy
xiaojun Liu, China
E25-615
Long-term outcomes of MR-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma
Guus Grimbergen, The Netherlands
E25-684
Efficacy and Safety of SBRT for Adrenal Metastases in oligometastatic-disease
Maria del Carmen Saiz Guisasola , Spain
E25-765
Ultra- and Moderately Hypofractionated Radiotherapy for Inoperable Cholangiocarcinoma: A single institution retrospective analysis
Saheli Saha, India
E25-804
prognostic impact of sarcopenia and surgical timing in locally advanced esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy
QIFENG WANG, China
E25-833
Predictors of toxicity in liver SBRT
CAROLINA DE LA PINTA, Spain
E25-842
Skeletal muscle measured on radiotherapy planning CT scans provides predictive utility on early mortality following oesophageal chemoradiotherapy
Christopher Bleaney, United Kingdom
E25-68
Patient and clinician engagement to develop GastroSCOPE – a proposed phase 2 UK study of high dose radiotherapy for inoperable gastric cancer
Sarah gwynne, United Kingdom
E25-984
Clinical outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with macrovascular invasion in a predominantly non-viral cohort
Jose Paul, India
E25-1363
Image-guided carbon ion stereotactic radiotherapy of hepatocellular carcinoma: paving the way for MR-guided online adaptive therapy
Sebastian Regnery, Germany
E25-1438
Feasibility and outcomes of patients with pancreatic cancer treated on the 1.5 MR-Linac in an Australian public hospital setting
Miki Wada, Australia
E25-1466
Evaluating efficacy of two AI auto-contouring algorithms for abdominal organs at risk (OAR) delineated in liver stereotactic body radiotherapy (SBRT)
Matthew Lee, United Kingdom
E25-1486
Does deep inspiration breath hold (DIBH) compress abdominal organs thus complicating radiotherapy for abdominal cancer?
George (Guang) Li, USA
E25-1553
Association between liver volume reduction and liver function decline after radiotherapy for hepatocellular carcinoma
Hiroshi Doi, Japan
E25-1632
Determinants of self-perceived health in gastric cancer patients in Albania.
Fatjona Kraja, Albania
E25-1664
Clinical and dosimetric outcomes of Stereotactic MR-guided adaptive radiotherapy (SMART) reirradiation for Liver Metastases
ELENA MORENO OLMEDO, United Kingdom
E25-1780
Radiology in Focus- A Survey of Imaging Modality Use in Oesophago-Gastric (OG) Cancer Evaluation and Target Volume Delineation (TVD)
Nicholas Gomez, United Kingdom
E25-1881
STEREOTACTIC RADIOTHERAPY WITH SIMULTANEOUS INTEGRATED PROTECTION FOR PANCREATIC ADENOCARCINOMA ABUTTED TO VISCERAL ORGANS: A PROSPECTIVE STUDY
Marco Lorenzo Furio Bonu', Italy
E25-129
Magnetic resonance imaging to define gross tumour volume for radiotherapy in patients with gastric adenocarcinoma: a scoping review
Owen Nicholas, United Kingdom
E25-1898
Hepatic metastases SBRT: what can CECT features tell us about outcome prediction and follow up? A single-center retrospective study
Michele Aquilano, Italy
E25-2077
Real-world clinical outcomes of stereotactic MR-guided adaptive radiotherapy (SMART) for localized pancreatic cancer: A retrospective cohort analysis
ELENA MORENO OLMEDO, United Kingdom
E25-2109
Stereotactic Body Radiotherapy (SBRT) for treatment of multiple liver metastases: dosimetric and clinical analysis
Mauro Loi, Italy
E25-2116
Concurrent Chemoradiation Outperforms Chemotherapy Alone in the Treatment of Unresectable Biliary Tract Cancers: A Meta-analysis.
Alessio Giuseppe Morganti, Italy
E25-2445
Robotic stereotactic body radiotherapy for malignant liver lesions: Local control and overall survival – a Monoinstitutional study.
Georgios Skazikis, Germany
E25-2454
Dose accumulation and its correlation with toxicity and clinical outcome in MR-guided pancreatic SABR
Rekaya Shabbir, United Kingdom
E25-2470
MRI-Guided Stereotactic Body Radiation Therapy for oligometastatic splenic lesions - Initial experience.
Lyndsey Edwards, Australia
E25-2554
Impact of reduced PRV margins on OAR doses for pancreas SABR treatments using the Elekta Unity MR-Linac
Robert Chuter, United Kingdom
E25-2795
Results of the EORTC survey on the management of non-metastatic pancreatic adenocarcinoma: a focus on radiotherapy.
Christelle Bouchart, Belgium
E25-2801
Radiomics-based Prediction of Lymph Node Regression after Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
QIFENG WANG, China
E25-267
Discordance between clinician and patient reported outcomes of acute esophageal toxicities in patients of NSCLC treated with radical IMRT
Tapesh Bhattacharyya, India
E25-2859
Survival and Patterns of Failure in Oligometastatic Esophagogastric Cancer
Orly Yariv, Israel
E25-3000
Radiotherapy for oesophagogastric cancers in the UK: volume, variation & quality
Christopher Bleaney, United Kingdom
E25-3061
Clinical results of proton beam therapy for patients with HCC: A merit of the BCLC staging on prognosis prediction
Takahiro Waki, Japan
E25-3073
A single centre experience of hepatocellular carcinoma (HCC) liver SABR: Clinical audit, outcomes and evaluation of local relapse pattern.
Carmen Canadillas-Navero, Spain
E25-3141
Assesing the dosimetric impact of abdominal compression use in distal oesophago-gastric cancer radiotherapy.
Nicholas Gomez, United Kingdom
E25-3154
Impact of larger tumor lengths on survival in esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery
Samir Batham, India
E25-3173
Preoperative chemoradiotherapy for esophageal and esophagogastric junction carcinoma: Single institutional results utilizing an extended CROSS regimen
Hossein Hemmatazad, Switzerland
E25-3246
Cervical Esophagus and Stomach Radiation Dose on Anastomotic Leaks in Esophageal Cancer after Neoadjuvant Chemoradiation and McKeown Esophagectomy
Chen Yang, China
E25-3275
Is Less More in Pancreatic Cancer?
Marta Bonet, Spain
E25-3312
Stereotactic-Ablative-Radiotherapy with Standard LINAC in Locally-Advanced-Pancreatic-Cancer: Resectability and Histopathological-Results
Barbara Gabriela Salas Salas, Spain
E25-295
Clinical outcomes with addition of stereotactic body radiation therapy in patients with hepatocellular carcinoma from a tertiary care centre in India
Ajit Solanky, India
E25-3359
Baseline coronary artery calcification burden and cardiovascular risk in esophageal cancer patients undergoing radiotherapy: is intervention needed?
Renliang Xue, The Netherlands
E25-3414
Radiotherapy dose intensification concomitant to capecitabine after induction chemotherapy for locally advanced pancreatic carcinoma: early results.
Nadia Di Muzio, Italy
E25-3460
Re-irradiation in recurrent esophageal cancer: toxicity and survival
Chiara Mattioli, Italy
E25-3493
Unexpected large variations in target and OAR delineations in SBRT for perihilar cholangiocarcinoma - QA of a prospective multicentre trial
Suus van Loosbroek, The Netherlands
E25-3545
Stereotactic body radiotherapy (SBRT) for nonsurgical cholangiocarcinoma.
Jesús Romero, Spain
E25-3607
Safe dose constraints for stomach and duodenum with carbon-ion radiotherapy
Hirokazu Makishima, Japan
E25-3679
Matched pair dosimetric comparison of CBCT-guided SBRT versus MR-LINAC in patients with liver malignancies.
sally Elkhamisy abdelhaleem, Germany
E25-3682
Findings of the PROTIEUS trial pre-accrual quality assurance contouring assessment – the importance of the benchmark case
Fiona Williams, United Kingdom
E25-3718
Low-dose involved-field RT plus immunochemotherapy showed excellent efficacy and low toxicities in unresectable LA-ESCC: a prospective phase II study
Yue-Yun Chen,
E25-3730
Stereotactic-ablative-Radiotherapy as a local treatment for refractory unresectable hepatocellular-carcinoma
Barbara Gabriela Salas Salas, Spain
E25-297
Stereotactic body radiotherapy compared to celiac plexus block for the management of pancreatic cancer associated pain: A systematic review
Aisling Barry, Ireland
E25-3819
Dosimetry comparison of 3DCRT and VMAT in Esophageal cancer treated with NeoadjuvantChemoRadiotherapy and correlation with postoperative complications
PRAGNA GS, India
E25-3830
Intercontinental Perspectives on Oligometastasis in Esophageal and Gastric Cancer: A Comparative Study with European Findings.
Tiuri Kroese, Switzerland
E25-3890
Patterns of Failure after Radical Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: The Experience of a Center.
Luísa Samarão, Portugal
E25-4014
The use of stereotactic radiotherapy in the case of recurrence of pancreatic cancer after surgery - own experience.
Agnieszka Namysł-Kaletka, Poland
E25-4056
Exploring Acute Toxicity and Potential Implications of Stereotactic Body Radiation Therapy for Liver Lesions: A Single Institution Experience
Nikolay Tolev, Bulgaria
E25-4059
A Decision Tree Model for Predicting Local Control in Liver Metastases Treated with SBRT
Ahmed Allam Mohamed, Germany
E25-4070
5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy Targeting the Primary Tumor for metastatic Pancreatic Cancer
Mohamed Schumann, Germany
E25-4126
Quantifying the benefit of daily on-table adaptation in reducing gastric and duodenal NTCP during stereotactic MR guided adaptive radiotherapy (SMART)
Kasia Owczarczyk, United Kingdom
E25-4140
SBRT in elderly patients with pancreatic cancer: outcomes and toxicity
Gian Marco Petrianni , Italy
E25-4155
Impact of muscle mass loss on survival during NCRT in patients with locally advanced ESCC: a multi-center retrospective study in china (TIMES study)
Jie Zhu, China
E25-315
MRI-Guided Stereotactic Radiotherapy for Pancreatic Tumours (SMART) : First Report of a Prospective Study in Spain
Daniela Gonsalves, Portugal
E25-4158
The role of Stereotactic Body Radiation Therapy in the treatment of oligometastatic hepatocellular carcinoma
Lorenzo Lo Faro, Italy
E25-4278
Decadal outcomes, recurrence trends and prognostic factors in esophageal carcinoma: Insights from the CROSS protocol
Jyoti Sharma, India
E25-4323
Outcomes of Breath Hold-Based Stereotactic Body Radiotherapy for Hepatocellular Carcinoma from a Tertiary Cancer Centre in India.
Shirley Lewis, India
E25-4355
Single centre experience with Stereotactic Ablative Body Radiotherapy for liver oligometastases
Carmen Canadillas-Navero, Spain
E25-4436
The Long-term Prognostic Value of 18F-FLT Versus 18F-FDG PET in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Study
QIFENG WANG, China
E25-450
Liver SBRT in more than 4 fractions: local control and recurrence patterns
Alizée RENAN, France
E25-540